Retrospective Analysis of Clinical Outcomes in Patients with Immunoglobulin A Nephropathy and Persistent Hematuria Following Renin-Angiotensin System Blockade

Jingjing Chen; Shao Liu; Hui Xu; Wei Wang; Yanyun Xie; Wenbin Tang; Qiongjing Yuan; Li Zheng; Lizhen Lin; Shuangshuang Fu; Jinmei Shen

doi:10.12659/MSM.922839

22 June 2020: Clinical Research

Retrospective Analysis of Clinical Outcomes in Patients with Immunoglobulin A Nephropathy and Persistent Hematuria Following Renin-Angiotensin System Blockade

Jingjing Chen ^12ACE , Shao Liu ^1ADE , Hui Xu ^23AF* , Wei Wang ^3BC , Yanyun Xie ^3B , Wenbin Tang ^3B , Qiongjing Yuan ^3B , Li Zheng ^4D , Lizhen Lin ^35F , Shuangshuang Fu ^6F , Jinmei Shen ^7C

DOI: 10.12659/MSM.922839

Med Sci Monit 2020; 26:e922839

Authors information Article notes Copyright and License information

View HTML version

Figure 2 Effect of RASB on the decreased percentage of hematuria. The decreased percentage of hematuria was significantly higher in RASB treated than untreated patients (p=0.01). RASB, rennin-angiotensin system blockers.

Back to the Article

Retrospective Analysis of Clinical Outcomes in Patients with Immunoglobulin A Nephropathy and Persistent Hematuria Following Renin-Angiotensin System Blockade

Your Privacy